Less Ads, More Data, More Tools Register for FREE

Thursday broker round-up UPDATE

Thu, 23rd Oct 2014 08:33
Abcam: FinnCap moves target price from 390p to 400p keeping a hold recommendation.Anglo American: Investec places its target price (prev.: 1603p) under review keeping its buy recommendation.Arbuthnot: Numis raises target price from 1150p to 1300p upgrading from hold to add.British American Tabacco: Jefferies reduces target price from 3900p to 3720p, while keeping a buy recommendation. JP Morgan reduces target price from 4549p to 4233p and leaves its overweight rating unchanged.Cranswick: Numis increases target price from 1296p to 1330p maintaining a hold recommendation. Peel Hunt ups target price from 1200p to 1250p retaining its hold recommendation.Debenhams: Peel Hunt lowers target price from 90p to 80p staying with its hold recommendation.Foxtons: Canaccord Genuity reduces target price from 382p to 228p downgrading from buy to hold.GlaxoSmithKline: Barclays upgrades to overweight with a target price of 1600p. Deutsche Bank cuts target price from 1420p to 1390p keeping a hold recommendation.Home Retail Group: Investec cuts target price from 240p to 225p leaving its buy recommendation unchanged.International Personal Finance: JP Morgan reduces target price from 644p to 530p and reiterates a neutral rating.Ladbrokers: Canaccord Genuity cuts target price from 162p to 150p retaining a hold recommendation. Numis downgrades to reduce with a target price of 100p.Norcos: N+1 Singer lowers target price from 27p to 22p and keeps a buy recommendation.SIG: Peel Hunt cuts target price from 275p to 240p, while its buy recommendation remains unchanged.UBM: Peel Hunt cuts target price from 680p to 650p, while upgrading from hold to buy.Whitbread: Credit Suisse reduces target price from 5000p to 4900p maintaining an outperform rating. SIG Anglo American Cranswick British American Tobacco Foxtons Glaxosmithkline Whitbread Inter. Pers. Norcros Home Reit Arbuthnot

Shares in this article

Related News

GSK drug momelotinib gains regulatory nods as VEXAS treatment
8 mins ago

GSK drug momelotinib gains regulatory nods as VEXAS treatment

(Alliance News) - GSK PLC on Friday announced that momelotinib has received orphan drug designation from the US Food & Drug Administration, and the Eu...

GSK's momelotinib receives orphan drug designation from US and EU watchdogs
1 hour ago

GSK's momelotinib receives orphan drug designation from US and EU watchdogs

(Sharecast News) - Drugmaker GSK said on Friday that its JAK inhibitor momelotinib has been granted orphan drug designation by both the US Food and Dr...

LONDON BRIEFING: UK economy contracts in April; Flutter to leave LSE
2 hours ago

LONDON BRIEFING: UK economy contracts in April; Flutter to leave LSE

(Alliance News) - The UK economy contracts 0.1% in April, Flutter Entertainment says it will delist from the London Stock Exchange in August, while Al...

Economic News Rolls-Royce + 7 more shares